Skip to main content
Clinical Trials/KCT0007801
KCT0007801Completed未知

Finding 50% effective dose of remimazolam for facilitating I-gel insertion with remifentanil target-controlled infusion

Ajou University Hospital0 sites25 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
25

Study Overview

Brief Summary

The remimazolam bolus dose for successful I-gel insertion in 50% of adult patients with Ce 3.0 ng/mL of remifentanil and without NMBAs was 0.280 ± 0.048 mg/kg. From the isotonic regression analysis, ED50 and ED95 were 0.244 (83% CI 0.213–0.313) mg/kg and 0.444 (95% CI 0.436–0.448) mg/kg, respectively.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
19(Year) to 65(Year) (—)
Sex
All

Inclusion Criteria

  • Adult patients aged 19-65 years with ASA score 1 or 2 scheduled for general anesthesia and eligible for I-gel use

Exclusion Criteria

  • BMI > 30 kg/m2
  • Patient refusal
  • Anticipated difficult airway
  • Anticipated difficult mask ventilation
  • COPD, astham, pneumonia, active URI
  • Risk of aspiration
  • Patients unable to response on verbal command
  • History of allergies to benzodiazepines
  • History of allergies to opioids
  • History of substance abuse/addiction
  • Pregnant or breastfeeding patients

Investigators

Sponsor
Ajou University Hospital

Similar Trials